Company intelligence / Profile preview

Novita Pharmaceuticals

New York, New York, United Statesnovita-pharm.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase 1 trial with excellent safety and pharmacokinetic profiles and preliminary efficacy signals. Phase 2 trial showed a Disease Control Rate of 76% and an Objective Response Rate of 21%, including 4 Partial Responses and 3 Complete Responses across multiple cancer types. Planning to begin enrollment in pivotal Phase 3 study of NP-G2-044 + PLD in platinum-resistant ovarian cancer in Q3 2025.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

NP-G2-044

Phase 2

Indications: Advanced solid tumors, Metastatic solid tumors

Partnerships

China Resources Double Crane Pharmaceutical (CRDC)

Beyond the preview

Go deeper on Novita Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novita Pharmaceuticals.

Explore the full profile